Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
essential tremor
Biotech
Biogen cans SAGE-324 collaboration after essential tremor fail
Biogen has administered the last rites to its collaboration with Sage Therapeutics on SAGE-324, scrapping the pact in the aftermath of a failed study.
Nick Paul Taylor
Sep 26, 2024 9:00am
Biogen, Sage flunk midphase essential tremor trial, stop study
Jul 24, 2024 8:10am
Jazz's ph. 2 essential tremor test misses endpoint
Jun 20, 2024 9:30am
Cala Health expands tremor-treating wearable to Parkinson's
Jun 16, 2023 10:06am
Praxis share price halved by tremor fail but still plans phase 3
Mar 3, 2023 9:05am
Neurocrine axes essential tremor program on phase 2 data
Aug 5, 2022 4:53am